Abstract Background Patients with relapsed or refractory peripheral T-cell lymphoma (R/R PTCL) treated with pralatrexate have previously shown superior overall survival (OS) compared to those who underwent conventional chemotherapy (CC. 15. 4 vs. 4. https://www.ngetikin.com/great-deal-Soderhamn-Footstool-Cover-great-pick/